Clinical Interests: Evaluation of therapies that may potentially improve the pulmonary and neurodevelopmental outcomes of preterm and term infants. Foster interest of neonatal trainees in clinical research project design, management, and completion.

Scholarly Focus: Clinical research activities that have the potential to improve the quality of life for NICU patients, not only while inpatients but also the long‐term improvement in their health. This focus includes these multiple clinical activities:

• Participation in studies that minimize the development of bronchopulmonary dysplasia such as inhaled nitric oxide, late surfactant treatment, and aerosolized surfactant administration to avoid need for evaluation of whether high dose erythropoietin treatment has neuroprotective effects in pre‐ term and term infants.
• Evaluation of the effect of slow-release intravenous iron therapy on neurodevelopment.

Research Funding:

2016‐2024  High‐dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) CCC. 1U01NS092764‐ 01A1, NINDS. Role: Co‐Investigator, Total Award: $10,100,000

2016-2023  Environmental Influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3)):

Developmental Impact of NICU Exposures (DINE).  UG3 OD023320. NICHQ. Role: Collaborator.

2022-2027            Trial of Darbepoetin plus slow-release intravenous iron to decrease or eliminate transfusions and iron deficiency in preterm infants. Role: Co-Investigator. NICHD. 1R01HD107003.

Administration/Education Roles: Design programs to educate future clinical researchers. Education responsibilities include training future pediatricians, neonatologists, neonatal nurse practitioners, and NICU nursing staff.